Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
CLN-619 by Cullinan Therapeutics for Relapsed Multiple Myeloma: Likelihood of Approval
CLN-619 is under clinical development by Cullinan Therapeutics and currently in Phase I for Relapsed Multiple Myeloma. According to GlobalData,...
CLN-619 by Cullinan Therapeutics for Refractory Multiple Myeloma: Likelihood of Approval
CLN-619 is under clinical development by Cullinan Therapeutics and currently in Phase I for Refractory Multiple Myeloma. According to GlobalData,...
CLN-619 by Cullinan Therapeutics for Ovarian Cancer: Likelihood of Approval
CLN-619 is under clinical development by Cullinan Therapeutics and currently in Phase I for Ovarian Cancer. According to GlobalData, Phase...
Risk adjusted net present value: What is the current valuation of Cullinan Therapeutics's CLN-619?
CLN-619 is a monoclonal antibody commercialized by Cullinan Therapeutics, with a leading Phase I program in Ovarian Cancer;Cervical Cancer;Endometrial Cancer....
Risk adjusted net present value: What is the current valuation of Cullinan Therapeutics's CLN-619?
CLN-619 is a monoclonal antibody commercialized by Cullinan Therapeutics, with a leading Phase I program in Metastatic Transitional (Urothelial) Tract...